Keymed Biosciences Inc. will hold its Annual General Meeting on 26 June 2026 at 2:00 p.m. in Chengdu, Sichuan. Shareholders will be asked to approve the following key items:

• 2025 Results Adoption The Board will present the audited consolidated financial statements and the reports of directors and the independent auditor for the year ended 31 December 2025.

• Board Composition and Remuneration Resolutions propose the re-election of Dr. Changyu Wang and Dr. Gang Xu as executive directors and Mr. Qi Chen as a non-executive director. Shareholders will also authorise the Board to determine directors’ remuneration.

• Auditor Mandate The meeting will consider re-appointing Ernst & Young as the Company’s external auditor until the conclusion of the next AGM and approve its remuneration.

• Share Issuance Mandate Management seeks authority to allot, issue or deal with additional shares or convertible securities up to 20% of the Company’s issued share capital (excluding treasury shares) during the mandate period. The mandate would include the power to grant related offers or options.

• Share Repurchase Mandate A separate resolution requests approval to repurchase shares on the Hong Kong Stock Exchange or other recognised markets, limited to 10% of issued share capital (excluding treasury shares). A further resolution links the two mandates, permitting any repurchased shares to be added to the 20% issuance limit.

• Administrative Details The register of members will close from 23 June 2026 to 26 June 2026, inclusive. Share transfers to qualify for AGM attendance must be lodged by 4:30 p.m. on 22 June 2026. All resolutions will be decided by poll, and proxy forms must reach Computershare Hong Kong Investor Services by 2:00 p.m. on 24 June 2026.

As of the notice date, the Board comprises six executive and non-executive directors and three independent non-executive directors.